MASLD - Approved/Available Therapeutics
Nov
13
2023
Ballroom BC
-
Hynes Convention Center
11:00
AM
- 12:30 PM EST
Speakers
Description
There continues to be ongoing need for effective therapies in MASLD. This session highlights treatment responses to available and approved therapeutics in MASLD.
Abstracts
- SINGLE ANASTOMOSIS DOUDENO-ILEAL BYPASS WITH SLEEVE GASTRECTOMY ALLEVIATES LIVER STIFFNESS AND CONTROLLED ATTENUATION PARAMETER IN OBESE PATIENTS – COMPARISON OF 4 MODALITIES
- LUBIPROSTONE REDUCES FAT CONTENT ON MRI-PDFF IN PATIENTS WITH MASLD
- TITLE: MAXIMIZING THE BENEFITS OF STATIN THERAPY FOR LIVER DISEASE PREVENTION: TARGETING PATIENTS WITH UNMET STATIN THERAPY NEEDS
- DAILY ASPIRIN THERAPY FOR THE TREATMENT OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE: A RANDOMIZED CONTROLLED TRIAL
- RISK OF ADVERSE LIVER AND RENAL OUTCOMES AFTER INITIATION OF A SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITOR VS. GLP-1 RECEPTOR AGONISTS AND DIPEPTIDYL PEPTIDASE-4 INHIBITORS AMONG US ADULT PATIENTS WITH TYPE 2 DIABETES AND MASLD
- DIGITAL IMAGE QUANTIFICATION OF THE ANTIFIBROTIC EFFECT OF SEMAGLUTIDE AND THE IMPACT OF LIVER FAT IN NONALCOHOLIC STEATOHEPATITIS
Objectives
- Attendees will describe outcomes of available pharmacologic agents and surgical intervention in the treatment of MASLD.
- Discuss the role of approved therapeutics in treatmnet of MASLD and other associated comorbidities.